The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis

Xiao Ma, Libin Huang, Zhiyin Huang, Jinsun Jiang, Chong Zhao, Huan Tong, Zhe Feng, Jinhang Gao, Rui Liu, Mingguang Zhang, Ming Zhou, Qinghua Tan, Ling Liu, Chengwei TangScientific 2020 · DOI

Abstract

Duodenal dysbiosis represents a significant infection risk for patients suffering from severe acute pancreatitis (SAP). While acid-suppressing drugs (ACDs) like esomeprazole (Eso) are frequently administered in Asian clinical settings to "rest" the pancreas, their impact on the duodenal microbiome during the acute phase of the disease has remained unclear. This randomized controlled trial evaluated 66 SAP patients to determine how esomeprazole affects duodenal microbial composition and infection rates during the first week of treatment. The study found that acid suppression significantly increased the occurrence of duodenal bacterial overgrowth (DBO) and Candida oesophagitis (CE), suggesting that the routine use of PPIs in SAP may carry substantial microbial risks.

Introduction

Severe acute pancreatitis (SAP) is a life-threatening inflammatory condition. A common therapeutic strategy, particularly in many Asian countries, is to "put the pancreas at rest" by inhibiting gastric acid secretion using proton pump inhibitors (PPIs). This approach is based on the physiological principle that reducing gastric acidity minimizes secretin-mediated pancreatic stimulation.

However, gastric acid serves as a primary biological barrier against ingested pathogens. Previous studies have linked long-term PPI use to small intestinal bacterial overgrowth (SIBO). This study sought to investigate whether the intensive, short-term use of PPIs during the critical first week of SAP disrupts the duodenal microbiota and increases the risk of secondary infections—a leading cause of mortality in SAP patients.

Methods

The researchers conducted a parallel randomized controlled trial involving 66 patients diagnosed with SAP. Participants were randomized in a 1:1 ratio into two groups: the esomeprazole group (Eso), receiving 40 mg/day, and the control group (Eso-N), which received no PPI.

Figure 1: Flowchart of patient enrollment and randomization process.

Key methodological steps included:

  • Sampling: On the seventh day of treatment, duodenal aspirates and mucosal brushes were collected via endoscopy.
  • Microbial Analysis: A dual-track approach was used. Traditional aerobic and anaerobic cultures quantified bacterial load, while 16S rRNA Illumina sequencing (V4-V5 regions) profiled the microbial community structure.
  • Bioinformatics: Sequences were clustered into Operational Taxonomic Units (OTUs) at 97% similarity using QIIME. Linear discriminant analysis Effect Size (LEfSe) was employed to identify significantly enriched taxa.
  • Controls: 20 healthy volunteers provided a baseline for normal duodenal microbiota.

Results

The study revealed that acid suppression led to rapid and profound changes in the duodenal environment.

Duodenal Bacterial Overgrowth (DBO)

The most prominent finding was the significant increase in DBO within the Eso group. As shown in the figure below, the occurrence of DBO in duodenal aspirates (panel a) was approximately 85% in the Eso group, compared to 42% in the Eso-N group (p < 0.001). Similar trends were observed in mucosal brush samples (panel b), though at slightly lower overall percentages.

Figure 2: Occurrence of duodenal bacterial overgrowth (DBO) in aspirates (a) and mucosal brushes (b) across Normal, Eso-N, and Eso groups.

Microbial Composition and pH

Intragastric pH was significantly higher in the Eso group (5.15) compared to the Eso-N group (2.70). This loss of acidity facilitated a shift in the duodenal microbiota. The Eso group showed an enrichment of taxa typically found in the oral cavity, such as Veillonella and Streptococcus, as well as the class Negativicutes and order Selenomonadales. This suggests that lowering gastric acidity allows oral microbes to survive transit and colonize the duodenum.

Secondary Infections

While clinical severity scores (APACHE II and Marshall scores) did not differ significantly between groups in the first week, there was a striking difference in fungal infections. Candida oesophagitis (CE) occurred in 24.2% of the Eso group compared to only 3.0% in the Eso-N group (p = 0.013), representing an 8-fold increase.

Discussion and Conclusion

This trial demonstrates that PPI-induced duodenal dysbiosis occurs much faster than previously thought, manifesting within just seven days in SAP patients. The "oral-to-gut" microbial pipeline enabled by acid suppression leads to a homogenized, potentially pathogenic duodenal environment.

The 8-fold spike in Candida infections is a critical "aha" moment, highlighting the gastric acid barrier's role in controlling opportunistic fungal growth. While the dysbiosis did not immediately translate to worse clinical scores in the first week, it may serve as a "silent" risk factor for late-stage complications like infected pancreatic necrosis, which typically develops 4–8 weeks after onset.

In conclusion, acid suppression significantly increases DBO, duodenal dysbiosis, and fungal infection risk during the early phase of SAP. Clinicians should consider a more restrictive use of acid-suppressing medications to mitigate these microbial risks and potentially reduce the incidence of late-stage pancreatic infections. Future multi-center trials are needed to confirm if avoiding routine PPI use improves long-term outcomes in SAP.

Summary updated

Abstract

Duodenal dysbiosis may be potential infection risks in patients with severe acute pancreatitis (SAP). Acid-suppression drugs (ACDs) are widely used in SAP patients in Asian countries. However, the impact of ACDs on duodenal microbiota during the early phase of SAP is still unknown. This randomized controlled clinical trial evaluated the impacts of esomeprazole (Eso), one of ACDs on duodenal microbiota during the first week of SAP with duodenal aspirates culture and 16sRNA Illumina sequencing analysis. 66 patients were randomized as 1:1 ratio into Eso group (Eso 40 mg/day) and Eso-N group (no Eso). The occurrence of duodenal bacterial overgrowth (DBO) was significantly higher in Eso group (about 85%) than that in Eso-N group (about 42%). The duodenal microbiota of the SAP patients shifted away from that of the normal control. There were differences between the Eso-N and Eso groups including enriched abundances of the class Negativicutes, order Selenomonadales and genus Veillonella. Acid suppression significantly increased incidence of Candida oesophagitis (CE) by 8-folds but did not increase other infectious events. In conclusion, acid suppression greatly increased the occurrence of DBO, duodenal dysbiosis and CE during the first week of SAP. Restrictive use of acid-suppressing medications might be helpful to reduce CE and potential risk of pancreatic infection in SAP patients.Trial registration: Chictr.org, ChiCTR-IPR-16008301, Registered April 18 2016, http://www.chictr.org.cn/showproj.aspx?proj=14089 .
BibTeX
@inproceedings{ma2020impacts,
  author = {Xiao Ma and Libin Huang and Zhiyin Huang and Jinsun Jiang and Chong Zhao and Huan Tong and Zhe Feng and Jinhang Gao and Rui Liu and Mingguang Zhang and Ming Zhou and Qinghua Tan and Ling Liu and Chengwei Tang},
  title = {{The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-77245-1},
}
Figure